Methods: We isolated CD3 T cells from malignant pleural effusion or primary tumor tissues of 30 lung cancer patients, and examined their immunophenotypes including surface markers (CD4 and CD8), proliferative index (Ki67), as well as inhibitory receptors (PD-1, TIM3, and CTLA4). Tumor-reactive T cells were subject to in vitro daily treatment of a DNA methyltransferase inhibitor, decitabine, for 72 h. The percentages of polyfunctional T cells before and after treatment were determined by intracellular staining of TNF-α, IFN-γ, IL-2 and CD107a, followed by flow cytometric analysis.
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Results: We discovered that malignant pleural effusion is an abundant source of tumor-reactive T cells. T cells in the malignant pleural effusion or primary lung cancer tissues have higher CD4/CD8 ratios, as compared with peripheral blood mononuclear cells from healthy volunteers. Notably, around 60% (range 20-90%) of T cells exhibited the exhausted phenotype and expressed at least one inhibitory receptors. Decitabine treatment significantly increased polyfunctionality of PD1+ T cells in certain patients. Background and Aims: Osimertinib has been approved by the US Food and Drug Administration (FDA) for non-small lung cancer (NSCLC) harboring acquired T790M mutation that have progressed while on other EGFR (Epidermal growth factor inhibitor)-inhibiting therapy. We compare the progression-free survival of patients whose T790M mutation was identified by liquid biopsy as compared with those by tissue sampling.
Methods: This is a retrospective cohort study conducted in Hong Kong that included 139 Chinese patients with advanced NSCLC who have disease progression after first line EGFR tyrosine kinase inhibitor and received osimertinib upon detection of T790M mutation, either by liquid biopsy (by identification of circulating tumor DNA) or by tissue rebiopsy. The primary end point is progression-free survival.
Results: Patients with EGFR T790M mutation detected by tissue sampling (n = 37) have significantly better progression free survival than those by peripheral blood liquid biopsy (n = 102) (PFS 380 vs 213 days, hazard ratio 0.576, 95% CI 0.359 -0.925, P value = 0.021). A small subgroup with positive liquid biopsy but concomitant negative tissue result (n = 6) have the lowest PFS among the different cohort (Median PFS = 57 days).
Conclusion:
Tissue re-biopsy for T790M mutation is preferred for patients who have NSCLC that progressed after first-line tyrosine kinase inhibitor. For cases that only have confirmatory liquid biopsy results, clinician should inform their patient that the expected PFS may be significantly shorter than those previously reported in literature. 
